Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NapaJen Pharma Inc.

www.napajen.com

Latest From NapaJen Pharma Inc.

Asia Deal Watch: Zogenix Partners Japanese Rights To Pediatric Epilepsy Therapy To Nippon Shinyaku

Nippon Shinyaku obtains rights to sell Dravet and Lennox-Gastaut syndrome drug Fintepla in its home market. Sun Pharma increases its ownership stake in Russia’s PJSC Biosintez.

Asia Pacific Commercial

Venture Funding Deals: Vedanta Raises More Cash To Advance Microbiome Candidates

Cancer drug-developer Black Diamond emerges from stealth mode with Series A and closes Series B in the same month, while aging-focused Juvenescence closes its initial tranche and looks complete Series B by the end of the quarter. 

Deals Financing
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Immune Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • NapaJen Pharma Inc.
  • Senior Management
  • Hironori Ando, Pres. & CEO
    Seiichi Okabe, CFO
    Kenji Arima, PhD, Chief Dev. Officer
    Kazuo Sakurai, PhD, CSO
  • Contact Info
  • NapaJen Pharma Inc.
    Phone: (650) 685-2429
    33 Airport Blvd., #527
    Burlingame, CA 94010
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register